Chimeric Antigen Receptor–Modified T Cells and T Cell–Engaging Bispecific Antibodies: Different Tools for the Same Job
Sign Up to like & getrecommendations! Published in 2021 at "Current Hematologic Malignancy Reports"
DOI: 10.1007/s11899-021-00628-2
Abstract: Both chimeric antigen receptor (CAR) T cells and T cell–engaging antibodies (BiAb) have been approved for the treatment of hematological malignancies. However, despite targeting the same antigen, they represent very different classes of therapeutics, each… read more here.
Keywords: cell engaging; antigen; car cells; antigen receptor ... See more keywords
CD3 Target Affinity Chromatography Mass Spectrometry as a New Tool for Function-Structure Characterization of T-Cell Engaging Bispecific Antibody Proteoforms and Product-Related Variants.
Sign Up to like & getrecommendations! Published in 2023 at "Analytical chemistry"
DOI: 10.1021/acs.analchem.2c03827
Abstract: T-cell engaging bispecific antibodies (TCBs) targeting CD3 and tumor-specific antigens are very promising therapeutic modalities. Since CD3 binding is crucial for the potency of TCBs, understanding the functional impact of CD3 antigen-binding fragment modifications is… read more here.
Keywords: cd3; cell; bispecific antibody; cell engaging ... See more keywords
PAX8 lineage-driven T cell engaging antibody for the treatment of high-grade serous ovarian cancer
Sign Up to like & getrecommendations! Published in 2021 at "Scientific Reports"
DOI: 10.1038/s41598-021-93992-1
Abstract: High-grade serous ovarian cancers (HGSOC) represent the most common subtype of ovarian malignancies. Due to the frequency of late-stage diagnosis and high rates of recurrence following standard of care treatments, novel therapies are needed to… read more here.
Keywords: cell engaging; serous ovarian; grade serous; high grade ... See more keywords
One size does not fit all: navigating the multi-dimensional space to optimize T-cell engaging protein therapeutics
Sign Up to like & getrecommendations! Published in 2021 at "mAbs"
DOI: 10.1080/19420862.2020.1871171
Abstract: ABSTRACT T-cell engaging biologics is a class of novel and promising immune-oncology compounds that leverage the immune system to eradicate cancer. Here, we compared and contrasted a bispecific diabody-Fc format, which displays a relatively short… read more here.
Keywords: one size; antigen binding; cell engaging; size fit ... See more keywords
Strategies for clinical dose optimization of T cell-engaging therapies in oncology
Sign Up to like & getrecommendations! Published in 2023 at "mAbs"
DOI: 10.1080/19420862.2023.2181016
Abstract: ABSTRACT Innovative approaches in the design of T cell-engaging (TCE) molecules are ushering in a new wave of promising immunotherapies for the treatment of cancer. Their mechanism of action, which generates an in trans interaction… read more here.
Keywords: oncology; dose optimization; clinical dose; cell engaging ... See more keywords
Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies
Sign Up to like & getrecommendations! Published in 2021 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2021-002444
Abstract: Background Bispecific T cell engagers represent the majority of bispecific antibodies (BsAbs) entering the clinic to treat metastatic cancer. The ability to apply these agents safely and efficaciously in the clinic, particularly for solid tumors,… read more here.
Keywords: cell engaging; engaging bsabs; affinity; cd3 affinity ... See more keywords
A Probody T Cell–Engaging Bispecific Antibody Targeting EGFR and CD3 Inhibits Colon Cancer Growth with Limited Toxicity
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Research"
DOI: 10.1158/0008-5472.can-21-2483
Abstract: A conditionally active EGFR-CD3 T cell–engaging Probody therapeutic expands the safety window of bispecific antibodies while maintaining efficacy in preclinical solid tumor settings. read more here.
Keywords: egfr cd3; probody; cancer; cell engaging ... See more keywords
Pre-clinical development of TNB-383B, a fully human T-cell engaging bispecific antibody targeting BCMA for the treatment of multiple myeloma.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.8034
Abstract: 8034Background: T-cell redirecting therapies such as CAR-T cells and T-cell engaging bispecific antibodies (T-BsAb) targeting B Cell Maturation Antigen (BCMA) have been highly efficacious against r... read more here.
Keywords: cell engaging; clinical development; pre clinical; development tnb ... See more keywords
Preferences among patients with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM) in the era of B-cell maturation antigen (BCMA)-directed T-cell–engaging therapies.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.e23309
Abstract: e23309 Background: BCMA-directed T-cell–engaging therapies have been introduced into clinical practice for the treatment of TCE RRMM. While efficacious, such treatments are associated with safety considerations such as cytokine release syndrome (CRS), immune effector cell-associated… read more here.
Keywords: directed cell; treatment; bcma directed; hospitalization ... See more keywords
Nephrotoxicity in Bispecific Antibodies Recipients: Focus on T-Cell-Engaging Bispecific Antibodies
Sign Up to like & getrecommendations! Published in 2024 at "OncoTargets and Therapy"
DOI: 10.2147/ott.s465679
Abstract: Abstract Recently, bispecific antibodies (BsAbs) are evolving the landscape of cancer treatment and have significantly improved the outcomes of relapsed or refractory cancer patients. As increasing BsAbs entered clinical practice, specific toxicities have emerged, and… read more here.
Keywords: cell engaging; bispecific antibodies; nephrotoxicity; bsabs recipients ... See more keywords